Domestic companies’ trouble in Brilinta’s substance patent
It was known although domestic pharmaceutical companies are competing over nullifying the patent of the AstraZeneca’s anticoagulant, ‘Brilinta,’ they are observed to have difficulties on the most important one, the substance patent. Thus, a part of the field has criticized thoughtless suits can h...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
